SEATTLE, March 19, 2015 – TapImmune Inc. (OTCBB: TPIV) is pleased to announce the appointment of David Laskow-Pooley to the Company’s Board of Directors.
David brings 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical and healthcare products. He has a successful track record of building, developing, operating and exiting start-up businesses, spin-outs from large corporations and business entities within large companies.
Mr. Laskow-Pooley is currently CEO of London Pharma Ltd, a clinical stage company re-purposing approved drugs through novel drug delivery technologies and is the Co-founder of Pharmafor Ltd. He was formerly Managing Director (UK) of Nasdaq- listed drug discovery platform company, OSI, and was part of the corporate team that developed and launched Tarceva for the treatment of lung cancer with marketing partners Roche and Genentech. He has had a distinguished career in multinational pharmaceutical companies including Glaxo SmithKline and Abbott, in addition to InVitrogen (Biotech Life Sciences) and Amersham, now GE Healthcare (Diagnostic Imaging). He currently serves as a non-executive director and Chairman of OBN Ltd, the leading industry representative for small to medium enterprises (SME’s) in the UK.
Dr. Glynn Wilson, Chairman & CEO of TapImmune, stated: “We welcome David to the TapImmune Board. His wealth of experience and successful track record in building and operating pharmaceutical organizations, and specifically in leading a company with clinical assets for the treatment of metastasized cancers is particularly relevant. We look forward to his guidance as we execute our Phase II clinical programs and grow our development pipeline, while enhancing our corporate governance.”
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious disease. The Company’s, peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website atwww.markertherapeutics.com for details.
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.
Glynn Wilson, Ph.D.
Chairman & CEO
Kirin M. Smith
Chief Operations Officer
Chief Communications Officer
J. Streicher Capital, LLC